Monitor the ASH presentation on Dec 14 for updated vascular anomalies data and the regulatory update that follows; also watch for the Phase 3 1L breast cancer trial design confirmation by year-end 2026 and initiation in early 2027.
Drugs in focus
RLAY drug pipeline →zovegalisib
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- The Phase 3 ReDiscover-2 trial is expected to complete enrollment in mid-2027, meaning a potential FDA approval filing would likely follow in 2028 at the earliest.
- Next catalyst
- None dated
What to watchThe ASH oral presentation on December 14, 2026, is the next catalyst: updated ReInspire data in vascular anomalies and a company call with a regulatory update. Positive data could support the differentiated profile and potentially provide a path to registration, while a negative or ambiguous update would be a neutral to slightly negative outcome.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $17.00entry
- T+1 · 11d ago +9.41%α +9.10% · $18.60
- T+5 · 5d ago +6.35%α +3.06% · $18.08
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Relay Therapeutics reported Q3 2026 net loss of $81.7M ($0.37 per share), narrower than the $0.43 loss per share in Q3 2025 but wider than the consensus estimate of a $0.40 loss. Revenue was $0, below the $1.6M consensus. The company highlighted faster-than-expected enrollment in the Phase 3 ReDiscover-2 trial for 2L breast cancer (completion now estimated mid-2027), upcoming ASH data for zovegalisib in vascular anomalies, and a cash position of $848.6M sufficient into 2029.
Key Financial Metrics
Key Facts
- Net loss of $81.7M ($0.37 per share) vs $74.1M ($0.43 per share) in Q3 2025; consensus was $-0.40 EPS
- Revenue of $0 vs consensus $1.6M; no license revenue in the quarter
- Cash, cash equivalents and investments of $848.6M as of Sep 30, 2026, down from $910.9M at Jun 30, 2026; runway into 2029
- Phase 3 ReDiscover-2 trial in 2L breast cancer estimated to complete enrollment in mid-2027, about one year faster than recent benchmarks
- Updated ReInspire data for zovegalisib in vascular anomalies to be presented at ASH on Dec 14, 2026; regulatory update to follow
- Shannon Campbell appointed Head of Commercial; previously CCO at Merus and senior roles at Novartis
- New mutant-selective TIE2 inhibitor program announced, in late-stage preclinical development
- FDA approved LYRFIGTU (lirafugratinib) for FGFR2 fusion cholangiocarcinoma; licensed to Elevar Therapeutics
Financial Impact
Net loss of $81.7M in Q3 2026, cash burn of ~$62.3M from Q2 to Q3 2026; cash runway into 2029
Risk Factors
- No revenue in Q3; pre-commercial stage with no approved products (lirafugratinib licensed out)
- Cash burn rate of ~$62M/quarter; $848.6M provides runway into 2029 but requires continued trial execution
- Phase 3 ReDiscover-2 enrollment completion mid-2027 leaves no near-term catalyst from that trial
- Competitive landscape for PI3Kα inhibitors in breast cancer and vascular anomalies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395819 |
Track record
21 reports on RLAY
6 of 10 bullish or bearish reports moved the stock their way by T+60. Best: +65.12% at T+60 after the May 19, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $17.68 Now $17.27 −2.29% settles Feb 12
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $17.00 Now $17.27 +1.59% settles Feb 3
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $17.44 Now $17.27 −0.97% settles Feb 1
- Oct 7, 20265w ago 144 Neutral 2/10 Entry $17.41 Now $17.27 −0.80% settles Jan 5
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $17.95 Now $17.27 −3.79% settles Jan 4
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $18.89 Now $17.27 −8.58% settles Dec 4
- Aug 28, 202611w ago Insider Cluster Bearish 6/10 Entry $18.77 Now $17.27 +7.99% settles Nov 23
- Aug 18, 202612w ago Insider Cluster Bearish 5/10 Entry $20.74 to $19.72 Now $17.27 +16.73% ▲ +4.92% +4.09% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers